Evaluate Companies

 
News Articles for Evaluate Companies top ^
Infoblox Inc. (NYSE:BLOX), the network control company, today introduced a free DNS-based evaluation product to help find malware carefully hidden by cybercriminals inside enterprise networks.
Sign-up for You’ve Got Malware: Infoblox Introduces Free Product Evaluation to Find the DNS Footprints of Cybercrime Inside Enterprise Networks investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159279&ProfileId=051205&sourceType=1 BAIE VERTE, NL --
Sign-up for Rambler and Maritime Agree to Evaluate the Viability of Restarting the Past Producing Hammerdown Gold Mine investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma.
Sign-up for Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) announced today a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299). The Phase 1/2 trial will evaluate the investigational combination of Opdivo and galunisertib as a potential treatment option for patients with advanced (metastatic and/or unresectable) glioblastoma, hepatocellular carcinoma and non-small cell lung cancer.
Sign-up for Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors investment picks
2015/1/20
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G030813-001&sourceType=1 http://www.marketwire.com/library/MwGo/2015/1/19/11G030813/80146_saba-1146932318974.jpg REDWOOD SHORES, CA--(Marketwired - January 20, 2015) - Saba (OTC PINK: SABA), a global leader in cloud based intelligent talent management solutions, today provided an update on its previously announced process to evaluate strategic alternatives.
Sign-up for Saba Provides Update on Its Evaluation of Strategic Alternatives investment picks
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif.
Sign-up for New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma investment picks
OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer Canada NewsWire AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
New evaluation module features TI's smallest HD pico display chipset, resulting in brighter, more efficient displays DALLAS , Nov.
Sign-up for TI DLP® LightCrafter™ Display 3010 evaluation module enables HD projection in compact electronics investment picks
2014/11/4
PhotoMedex, Inc. (NasdaqGS and TASE:PHMD) announces the Company has entered into an Amended and Restated Forbearance Agreement (the "Amended Forbearance Agreement") with respect to its Credit Agreement dated May 12, 2014 and the Initial Forbearance Agreement dated August 25, 2014 by and among PhotoMedex, Inc. as borrower and the Lenders as parties thereto, and JPMorgan Chase Bank, N.A. (the "Administrative Agent"), acting on behalf of secured creditors as the administrative agent.
Sign-up for PhotoMedex Agrees to Amended Forbearance Agreement with Secured Creditors, Engages Canaccord Genuity to Evaluate Strategic Alternatives investment picks
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the last patient has been enrolled in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot ® Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males.
Sign-up for Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males investment picks
By Angela Chen Alliant Techsystems Inc. said it is evaluating any potential implications from Tuesday night's explosion of Orbital Sciences Inc.'s Antares rocket, a hint their plans to merge could be in jeopardy.
Sign-up for Alliant Tech evaluating merger plans after Orbital rocket explosion investment picks
Legion Partners says in letter that long history of underperformance has led to poor shareholder returns BEVERLY HILLS, Calif.
Sign-up for CalSTRS, Legion Partners Call On Perry Ellis Board To Form An Independent Committee To Evaluate Strategic Alternatives investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982831001&sourceType=1 http://media3.marketwire.com/logos/20120223-PROPH.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Prophecy Provides Background on Pulacayo Property and Commences Evaluation of Historic Tailings investment picks
WGL Holdings, Inc. (NYSE: WGL), through its subsidiary, Washington Gas Energy Systems ( WGESystems ), announced an agreement with Southern Company and the Electric Power Research Institute (EPRI) to test and evaluate a battery storage system at a 1-megawatt (MW) solar array in Cedartown, Ga.
Sign-up for Washington Gas Energy Systems to Evaluate Battery Storage System for Solar Energy in Cedartown, Georgia investment picks
2014/12/11
AHA Products Group announced today that KX Systems, a leader in high-performance database systems, particularly in financial services, has completed the evaluation of the AHA372 PCI-Express 20 Gbps GZIP Compression Accelerator with its kdb+ software.
Sign-up for AHA Announces Results from KX Systems Evaluation investment picks
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first patient enrollment in the STAR-VT ( S ubstrate T argeted A blation using the FlexAbility™ Ablation Catheter System for the R eduction of V entricular T achycardia) clinical trial, a prospective, multi-center, randomized study evaluating the safety and efficacy of the FlexAbility™ ablation catheter when used in ventricular tachycardia (VT) ablation procedures.
Sign-up for St. Jude Medical Begins Landmark Clinical Study to Evaluate Effectiveness of Ablation Procedures for Treatment of Ventricular Tachycardia investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G029445-001&sourceType=1 http://www.marketwire.com/library/MwGo/2015/1/2/11G029445/Logo1-1648716298.jpg LAS VEGAS, NV--(Marketwired - January 05, 2015) - Energous Corporation ("Energous" or "the Company") (NASDAQ: WATT), the developer of WattUp, a disruptive wire-free charging technology for electronic devices that provides power at a distance with complete mobility under full software control, today announced it has signed a collaboration agreement (CA) with Foxconn Interconnect Technology Limited (Foxconn). Under the terms of the agreement, Energous and Foxconn are working together to evaluate the WattUp technology to determine the suitability for future Foxconn products and solutions.
Sign-up for Foxconn Interconnect Technology and Energous Corporation Join Forces to Evaluate Wire-Free Charging Technology investment picks
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction.
Sign-up for Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials.
Sign-up for Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Evaluate Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Eurozone Inflation  |  Next: Evaluating Strategic Alternatives